Further characterisation of the gene targets, co-regulators and transcriptional complexes forming as a result of constitutive NF-κB/p52 activity will provide the foundation for new and more selective therapeutic strategies in fighting myeloma and other diseases that exploit the NF-κB pathway99. Here, NFKB2 is linked to plasma cell myeloma.